Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Mutant α-synuclein causes death of human cortical neurons via ERK1/2 and JNK activation.

Molecular brain | 2024

Synucleinopathies refer to a group of disorders characterized by SNCA/α-synuclein (α-Syn)-containing cytoplasmic inclusions and neuronal cell loss in the nervous system including the cortex, a common feature being cognitive impairment. Still, the molecular pathogenesis of cognitive decline remains poorly understood, hampering the development of effective treatments. Here, we generated induced pluripotent stem cells (iPSCs) derived from familial Parkinson's disease (PD) patients carrying SNCA A53T mutation, differentiating them into cortical neurons by a direct conversion method. Patient iPSCs-derived cortical neurons harboring mutant α-Syn exhibited increased α-Syn-positive aggregates, shorter neurites, and time-dependent vulnerability. Furthermore, RNA-sequencing analysis, followed by biochemical validation, identified the activation of the ERK1/2 and JNK cascades in cortical neurons with SNCA A53T mutation. This result was consistent with a reverted phenotype of neuronal death in cortical neurons when treated with ERK1/2 and JNK inhibitors, respectively. Our findings emphasize the role of ERK1/2 and JNK cascades in the vulnerability of cortical neurons in synucleinopathies, and they could pave the way toward therapeutic advancements for synucleinopathies.

Pubmed ID: 38444039 RIS Download

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


Anti-β-Actin Antibody (antibody)

RRID:AB_476744

This monoclonal targets slightly modified β-cytoplasmic actin N-terminal peptide, Ac-Asp-Asp-Asp-Ile-Ala-Ala-Leu-Val-Ile-Asp-Asn-Gly-Ser-Gly-Lys, conjugated to KLH

View all literature mentions

SAPK/JNK Antibody (antibody)

RRID:AB_2250373

This polyclonal targets SAPK/JNK

View all literature mentions

Phospho-p38 MAPK (Thr180/Tyr182) Antibody (antibody)

RRID:AB_331641

This polyclonal targets p38 MAPK, phospho (Thr180 / Tyr182)

View all literature mentions

Phospho-SAPK/JNK (Thr183/Tyr185) Antibody (antibody)

RRID:AB_331659

This polyclonal targets Phospho-SAPK/JNK (Thr183/Tyr185)

View all literature mentions

Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) (D13.14.4E) XP® Rabbit mAb (antibody)

RRID:AB_2315112

This monoclonal targets Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204)

View all literature mentions

Anti-Stage-Specific Embryonic Antigen-4 (antibody)

RRID:AB_177629

This monoclonal targets Stage-Specific Embryonic Antigen-4

View all literature mentions

TRA-1-60(S) (TRA-1-60(S)) Mouse mAb (antibody)

RRID:AB_2119059

This monoclonal targets TRA-1-60(S)

View all literature mentions

Anti-alpha Synuclein antibody [MJFR1] (antibody)

RRID:AB_2537217

This monoclonal targets alpha Synuclein

View all literature mentions

MAP2 antibody - Neuronal Marker (antibody)

RRID:AB_2138153

This polyclonal targets MAP2 antibody - Neuronal Marker

View all literature mentions